Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance

Lou, Feiran; Huang, James; Sima, Camelia S.; Dycoco, Joseph; Rusch, Valerie W.; Bach, Peter B.

doi:10.1016/j.jtcvs.2012.09.030

Cited by 255 publications

(203 citation statements)

References 15 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…23 After both surgery and SABR, an early manifestation of distant metastases represents the predominant pattern of disease failure. 6,13 The present finding that overall survival is correlated only with the Charlson Comorbidity Index is consistent with population-based data indicating that stage-specific 5-year survival rates in the Danish Lung Cancer Registry for patients with earlystage NSCLC and severe comorbidity were significantly lower than in patients without comorbid disease, with the survival impact of severe comorbidity found to be greatest during the first month after surgery, but persisting during long-term follow-up. 24 The findings of all these studies will add to clinical equipoise and should encourage enrollment in randomized clinical trials to better compare the effectiveness of surgery and SABR in patients with early-stage NSCLC.…”

supporting

confidence: 89%

Surgery versus stereotactic radiotherapy for patients with early‐stage non–small cell lung cancer

Senan

2013

Cancer

View full text Add to dashboard Cite

This study of outcomes after either surgery or stereotactic ablative radiotherapy for patients with early‐stage non–small cell lung cancer found that overall survival was correlated only with the Charlson Comorbidity Index, and that only tumor diameter was correlated with locoregional tumor control. These findings will increase clinical equipoise and facilitate patient inclusion into ongoing trials comparing both treatments.

show abstract

supporting

confidence: 89%

Surgery versus stereotactic radiotherapy for patients with early‐stage non–small cell lung cancer

Senan

2013

Cancer

View full text Add to dashboard Cite

show abstract

“…However, 20-30% of early stage NSCLC patients undergo a relapse even upon complete surgical resection of their tumor (32,33). Platinum-based adjuvant chemotherapy for NSCLC patients with stage IB-IIIA disease has been investigated in several clinical trials (34)(35)(36)(37).…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of ABCB1 in stage I lung adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. Cancer stem cell (CSC) properties have been recently proposed to explain tumor carcinogenesis and multidrug resistance in several human cancers, including non-small cell lung cancer (NSCLC). The present study examined the protein expression of three CSC-associated markers, namely ATP binding cassette subfamily B member 1 (ABCB1), aldehyde dehydrogenase 1 family member A1 (ALDH1A1) and cluster of differentiation (CD) 44, by immunohistochemistry in 194 NSCLC patients who underwent complete resection of NSCLC tumors. The association between the expression of these proteins and patient prognosis was evaluated to clarify the prognostic significance of CSC-associated markers in NSCLC patients. Positive staining for ABCB1 demonstrated a trend toward worse survival compared with negative staining in stage I-III NSCLC. Negative staining for ALDH1 or CD44 exhibited a trend toward worse survival compared with positive staining in stage I-III NSCLC. It was observed that patients with stage I lung adenocarcinoma (ADC) showing positivity for ABCB1 expression had significantly poorer survival than those with negative ABCB1 staining (P=0.03). Furthermore, stage I ADC patients with wild-type epidermal growth factor receptor (EGFR) who exhibited positive staining for ABCB1 had significantly shorter disease-free survival (DFS) compared with patients with negative staining for ABCB1 (P<0.01). Analyses by univariate and multivariate Cox proportional hazards models revealed that ABCB1-positive staining was significantly associated with DFS and was an independent prognostic factor (hazard ratio, 3.49; P<0.05) in these patients. These results suggest that ABCB1 protein expression is useful for predicting prognosis and selecting patients for post-operative therapy in stage I lung ADC patients, particularly those harboring wild-type EGFR.

show abstract

“…CT evaluation of response to treatment is usually dependent on morphologic changes in tumor and nodes. Lou et al [34] showed that CT detected 93% of new lung cancers and 61% of recurrences in a cohort of over 1000 patients after resection of earlystage non-small-cell lung cancer (NSCLC). Despite these results, there is currently no consensus on the optimal follow-up and surveillance program for patients with proven lung cancers.…”

Section: Screening For Lung Cancermentioning

confidence: 99%